Key takeaways
- GHK-Cu names a defined complex; “GLOW” names a blend listing GHK-Cu, BPC-157 and TB-500.
- The 2006 Miller randomized human trial of a GHK-Cu skin formulation had 13 completers; material sold online is not the formulation tested.
- 6AM Research found no published study or registered trial testing GHK-Cu, BPC-157 and TB-500 together in PubMed and ClinicalTrials.gov on 21 November 2026.
- The World Anti-Doping Agency lists BPC-157 and TB-500 as prohibited at all times under separate classes.
01GHK-Cu vs “GLOW” in one table
| Question | GHK-Cu | “GLOW” |
|---|---|---|
| Identity | Glycine, histidine and lysine form the three-amino-acid peptide GHK, which is bound to copper in GHK-Cu. | A blend name for GHK-Cu, BPC-157 and TB-500 in one vial. |
| Evidence tier | T1 for the design of a randomized human trial of a specific skin formulation, not a grade for every formulation. Material sold online is not the formulation tested. | No study tier for the blend itself. Evidence grades for individual components do not transfer. |
| Human data | Miller et al. (2006): 13 patients completed a randomized study after laser skin resurfacing. Among the measures was skin redness. Material sold online is not the formulation tested. | 6AM Research found no published human study or registered trial testing GHK-Cu, BPC-157 and TB-500 together in PubMed and ClinicalTrials.gov on 21 November 2026. |
| United States | The FDA nomination list places GHK-Cu in Category 1, under evaluation, for certain routes of administration only. | For the additional components, the Department of Health and Human Services draft compounding policy names BPC-157 and TB-500 individually and applies only when a product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. The notice says the draft “is not binding”. |
| United Kingdom | The emc medicines database returned no results for GHK, copper tripeptide or prezatide (21 Nov 2026); it is not the full UK register | The same for BPC-157 and TB-500 |
| Australia | The TGA says that “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” GHK-Cu has no entry by name in the Poisons Standard October 2026, which has group entries for copper compounds; we draw no scheduling conclusion of our own. | The October 2026 Poisons Standard lists BPC-157 and TB-500 in Schedule 4 and Appendix D, clause 5. These are component entries. |
| Sport | GHK-Cu is not named on the World Anti-Doping Agency’s 2026 or 2027 Prohibited List. WADA says a peptide not specifically named “may still be prohibited and may be harmful to health”. | The 2026 Prohibited List names BPC-157 under S0 and TB-500 under S2.3. Both are prohibited in and out of competition. |
02What differs, and what stays the same?
If you searched “ghk cu vs glow vs klow”, start with what each name identifies. The same GHK-Cu name appears in both ingredient lists. Neither list is a measurement of what is in a particular vial.
GHK-Cu: a defined complex
GHK-Cu identifies the peptide GHK bound to copper. It does not name a blend.
“GLOW”: three listed components
The name refers here to GHK-Cu, BPC-157 and TB-500 together.
“KLOW”: a fourth listed component
The “KLOW” label adds KPV to that list. For how the fourth ingredient changes what a lab report should show, see the “KLOW” guide.
The shared ingredient tells you where the names overlap. It does not make the blends interchangeable with GHK-Cu or with each other. A study of a GHK-Cu formulation is evidence about the formulation studied, not about what happens when other peptides are added.
03What did the human trial measure?
In 2006, Miller and colleagues randomized patients after laser skin resurfacing to skin-care formulations with or without GHK-Cu. Thirteen patients completed the trial. Researchers assessed redness and skin appearance and collected patient questionnaires. This is T1 for study design under 6AM Research’s evidence grades. It was a small trial of specific formulations. Material sold online is not the formulation tested.
For the blend, 6AM Research searched PubMed for names and synonyms of GHK-Cu, BPC-157 and TB-500, including searches with and without quotation marks and a broader search that also included thymosin beta names. It checked ClinicalTrials.gov by component. On 21 November 2026, those searches found no published study in any species or registered trial testing GHK-Cu, BPC-157 and TB-500 together.
A paper that discusses all three ingredients is not necessarily a study that tested them together. Check what the researchers actually compared.
04How to read the legal and sport records
- 14 May 2026FDA nomination list
The updated list places GHK-Cu in Category 1 for certain routes of administration only. Category 1 means the bulk substance is under evaluation.
- 1 October 2026Australian Poisons Standard
The October instrument names BPC-157 and TB-500 in Schedule 4, the prescription-only schedule, and in Appendix D, clause 5.
- 30 October 2026US draft compounding policy notice
The Federal Register describes a draft policy that “is not binding”. Its list names BPC-157 and TB-500 individually, and it applies only to products with a single active ingredient listed in its Appendix A.
United Kingdom. Regulation 46(1) of the Human Medicines Regulations 2012 prohibits selling or supplying, or offering to sell or supply, an unauthorized medicinal product. Regulation 2(1) defines a medicinal product by how it is presented or by its function, including pharmacological, immunological or metabolic action to restore, correct or modify a physiological function, or use for medical diagnosis.
Sport. The World Anti-Doping Agency’s 2026 list applies on the date of this comparison. Its explanatory notes for 2027 caution that a peptide can still be prohibited and harmful to health even if the list does not name it. See how to read the anti-doping categories.
05What we don’t know
- How GHK-Cu compares with the three-component blend in a controlled study. 6AM Research found no such comparison in PubMed or ClinicalTrials.gov on 21 November 2026.
- What is actually in a vial from its name alone. A name states a label claim; it does not identify a batch.
- Which listed peptides are present from a single purity percentage. That figure cannot establish each identity.
On a certificate of analysis, look for a matching batch number, a separate identity result for each listed peptide, and a separate measurement for each. A report on GHK-Cu alone cannot show whether BPC-157 or TB-500 was present. See how to read a certificate of analysis for the difference between identity, amount and purity.
This is a plain-English summary of public records, dated 21 November 2026, not legal or medical advice.